Skip to main content

Illinois Selects Tepnel CF Test for Newborn Screening

NEW YORK (GenomeWeb News) – Manchester, UK-based Tepnel Life Sciences today said that the Illinois Department of Public Health has selected its Elucigene CF-US test for two-stage testing of cystic fibrosis under a newly mandated screening program for all newborns in the state.
 
Tepnel’s test is designed for use on high-throughput capillary sequencers and detects 44 mutations in the cystic fibrosis transmembrane conductance regulator gene and their wild-type counterparts.
 
The Illinois DPH began validating the test early in 2008, Tepnel said. The first stage of the program calls for newborns to be tested for elevated levels of immunoreactive trypsin using a blood sample from the infant’s heel. If the infant’s IRT level is in the top 4 percent of the daily assay run, then their sample is tested for CF mutations using Tepnel’s test.
 

The Scan

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.